MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/100/0.1/20.06.25 | Real-time Bid/Ask 12:17:36 2024-06-03 EDT | ||
| 0.196 EUR / 0.198 EUR | +11.93% |
|
| 1 month | +25.71% | ||
| 3 months | +225.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 0.163 | -7.39% |
| 24-05-31 | 0.176 | +15.79% |
| 24-05-30 | 0.152 | +4.83% |
| 24-05-29 | 0.145 | -13.17% |
| 24-05-28 | 0.167 | +12.08% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 08:31 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME3GY9 |
| ISIN | DE000ME3GY94 |
| Date issued | 2023-11-13 |
| Strike | 100 $ |
| Maturity | 2025-06-20 (382 Days) |
| Parity | 10 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.181 € |
|---|---|
| Lowest since issue | 0.033 € |
| Spread | 0.002 € |
| Spread % | 0.98% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Warrants
- Warrant
